Toronto, Aug. 03, 2021 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (CSE: CMND) (“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, announces that Mark Haden has joined the Company’s Scientific Advisory Board (the “SAB”). The SAB’s initial focus will be providing guidance on the Company’s request for an Investigational New Drug review from the US Food and Drug Administration (“FDA”) for MEAI, for treating Alcohol Use Disorder (“AUD”).
A recognized leader in the field, Mr. Haden has spent his career working to advance the use of psychedelics in medicine. He currently serves as director of clinical research at Psygen Industries, a manufacturer of pharmaceutical-grade psychedelic drug products for clinical research and therapeutic applications and is an adjunct professor at the University of British Columbia School of Population and Public Health.
Mr. Haden has substantial research experience, including a leadership role in the PRIME study (Psilocybin Research Investigating Medical Efficacy), which explores psilocybin as an adjunct in the treatment of substance use disorders, and he has spent 10 years as the chairman and executive director of MAPS Canada (Multidisciplinary Association for Psychedelic Studies), an organization he founded. He has also dedicated over 25 years to working directly with patients through the Vancouver Coastal Health Addiction Services at the Pacific Spirit Community Health Centre.
He is a frequent keynote speaker on the topic of psychedelics and has been published in a number of journals, including the Canadian Journal of Public Health, International Journal of Drug Policy, Encyclopedia of Public Health, Harm Reduction Journal, Open Medicine, Journal of Psychoactive Drugs, and the Journal of Studies on Alcohol and Drugs. He was also instrumental in helping the Health Officers Council of British Columbia develop their position papers, lectures and presentations on issues regarding the regulation of illegal drugs.
“Mark is an important addition to our SAB. He is one of the world’s leading advocates for the legalization of psychedelics and a strong proponent of their medicinal value. His research into psychedelics and their potential to treat addiction parallels the work we are doing to develop therapies to manage AUD, and I am confident that his contribution to our efforts to secure FDA approval for MEAI will be invaluable,” commented Adi Zuloff-Shani, Ph.D., CEO of Clearmind.
Mr. Haden noted, “Clearmind’s innovative approach to harnessing the properties of psychedelics to create therapeutics for mental health issues has the potential to change millions of lives around the world. I have spent my career on a similar quest, and I am delighted to facilitate this effort in any way I can. I very much look forward to working with the talented team at Clearmind as well as the other distinguished members of the advisory board.”
About Clearmind Medicine Inc.
Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of two patent families. The first, “Binge Behavior Regulators”, has been granted in the U.S., Europe, China and India, with pending divisional applications in Europe and the U.S. The second, “Alcohol Beverage Substitute”, has been approved for a European patent, with pending applications in the U.S., China and India. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on the Canadian Securities Exchange under the symbol “CMND.”
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include submission of the relevant documentation within the required timeframe to the satisfaction of the relevant regulators and raising sufficient financing to complete the Company’s business strategy. There is no certainty that any of these events will occur. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.
Investing into early-stage companies inherently carries a high degree of risk, and investment into securities of the Company shall be considered highly speculative.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any province in which such offer, solicitation or sale would be unlawful.
Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.